clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02916537 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | United States of America | Q30 |
P582 | end time | 2017-08-28 | |
P921 | main subject | metastatic prostate carcinoma | Q55779807 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 20 | |
P859 | sponsor | Cancer Targeted Technology | Q30286547 |
P580 | start time | 2016-09-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA) |
Search more.